GSK’s Cervarix became the top of ‘Female Vaccine
The GSK’s(Yoo-seok Hong, Korean Branch President) uterine cervical cancer preventive vaccines, ‘Cervarix,’ has acquired additional approval for indication of vaginal intra-epithelial neoplasia and vulvar intra-epithelial neoplasia prevention from the Ministry of Food and Drug Safety(hereinafter r...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
